Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Drug Information » New Medical Therapies™

Cutaneous Candidiasis

January 13, 2003

Versicor reported positive results from a phase II trial investigating anidulafungin for the treatment of invasive candidiasis and candidemia. Data showed that 88 % (23/26) of subjects exhibited a global response rate with a loading dose of 200 mg followed by a 100 mg maintenance dose per day. Results also showed that 89 % (25/28) of subjects exhibited a response rate with an analogous anidulafungin regimen of 150 mg followed by 75 mg per day, and 81 % (21/26) of subjects with 100 mg followed by 50 mg. These rates compare favorably with rates reported in previous clinical trials with other agents, such as fluconazole, amphotericin B and caspofungin, which range from 56 % to 81 % in subjects with invasive candidiasis/candidemia. The drug was well tolerated and adverse events attributable to the treatment were infrequent and similar for each dose. The randomized, open-label trial enrolled approximately 120 subjects in the U.S. with invasive candidiasis/candidemia.